Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Accenture
Queensland Health
Dow
Medtronic
Deloitte
Fish and Richardson
Moodys
Chinese Patent Office
Fuji

Generated: December 11, 2017

DrugPatentWatch Database Preview

SANOFI AVENTIS US Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?

SANOFI AVENTIS US has one hundred and thirty-six approved drugs.

There are fifty-seven US patents protecting SANOFI AVENTIS US drugs.

There are one thousand and fifty-five patent family members on SANOFI AVENTIS US drugs in seventy-four countries and one hundred and fifty-one supplementary protection certificates in fifteen countries.

Summary for SANOFI AVENTIS US

International Patents:1055
US Patents:57
Tradenames:113
Ingredients:93
NDAs:136
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsDECAPRYNdoxylamine succinateTABLET;ORAL006412-015Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsMETAHYDRINtrichlormethiazideTABLET;ORAL012594-001Jun 16, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsSLO-PHYLLINtheophyllineTABLET;ORAL085204-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsBRONKODYLtheophyllineCAPSULE;ORAL085264-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsAPIDRAinsulin glulisine recombinantINJECTABLE;IV (INFUSION), SUBCUTANEOUS021629-002Dec 20, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsALLEGRAfexofenadine hydrochlorideSUSPENSION;ORAL021963-001Oct 16, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsAVALIDEhydrochlorothiazide; irbesartanTABLET;ORAL020758-001Sep 30, 1997DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsLOVENOX (PRESERVATIVE FREE)enoxaparin sodiumINJECTABLE;SUBCUTANEOUS020164-007Jun 2, 2000APRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsNASACORT ALLERGY 24 HOURtriamcinolone acetonideSPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsPRESAMINEimipramine hydrochlorideTABLET;ORAL011836-007Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsARAVAleflunomideTABLET;ORAL020905-001Sep 10, 1998► Subscribe► Subscribe
Sanofi Aventis UsDIABETAglyburideTABLET;ORAL017532-002May 1, 1984► Subscribe► Subscribe
Sanofi Aventis UsLORELCOprobucolTABLET;ORAL017535-002Jul 6, 1988► Subscribe► Subscribe
Sanofi Aventis UsALLEGRAfexofenadine hydrochlorideCAPSULE;ORAL020625-001Jul 25, 1996► Subscribe► Subscribe
Sanofi Aventis UsCHILDREN'S ALLEGRA ALLERGYfexofenadine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsALLEGRAfexofenadine hydrochlorideCAPSULE;ORAL020625-001Jul 25, 1996► Subscribe► Subscribe
Sanofi Aventis UsAMARYLglimepirideTABLET;ORAL020496-002Nov 30, 1995► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021492-002Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis UsCHILDREN'S ALLEGRA HIVESfexofenadine hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021909-003Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis UsNICODERM CQnicotineFILM, EXTENDED RELEASE;TRANSDERMAL020165-005Aug 2, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
nicotineTransdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrsNICODERM CQ5/30/2014
dronedarone hydrochlorideTablets400 mgMULTAQ7/1/2013
oxaliplatinInjection5 mg/mL, 40 mL vialELOXATIN3/23/2011
fexofenadine hydrochlorideOral Suspension30 mg/5 mLALLEGRA1/25/2010
docetaxelInjection40 mg/mL, 0.5 mL and 2 mL vialsTAXOTERE6/30/2009
clopidogrel bisulfateTablets300 mgPLAVIX3/4/2009
oxaliplatinInjection200 mg/40 mLELOXATIN7/16/2007
oxaliplatinInjection5 mg/mL, 10 mL and 20 mL vialsELOXATIN2/9/2007
oxaliplatinFor Injection50 mg/vial and 100 mg/vialELOXATIN2/9/2007
enoxaparin sodiumInjection100 mg/mL, 3 mL vialsLOVENOX12/7/2006
irbesartan and hydrochlorothiazideTablets300 mg/25 mgAVALIDE6/6/2006
zolpidem tartrateExtended-release Tablets6.25 mgAMBIEN CR2/24/2006
zolpidem tartrateExtended-release Tablets12.5 mgAMBIEN CR1/19/2006
irbesartan and hydrochlorothiazideTablets150 mg/12.5 mg and 300 mg/12.5 mgAVALIDE11/10/2004
irbesartanTablets75 mg, 150 mg and 300 mgAVAPRO5/25/2004

Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Sanofi Aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,205,276Zinc-free and low-zinc insulin preparations having improved stability► Subscribe
7,147,870Osmotic device containing pseudoephedrine and an H1 antagonist► Subscribe
6,331,635 Taxoids, their preparation and pharmaceutical compositions containing them► Subscribe
8,888,750Pen-type injector► Subscribe
9,028,454Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,876,782Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,622,136Transparent transdermal nicotine delivery devices► Subscribe
8,663,175Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,122,206Aqueous-based pharmaceutical composition► Subscribe
6,100,404 Erythromycin compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi Aventis Us Drugs

Country Document Number Estimated Expiration
Germany602006006870► Subscribe
Brazil9915939► Subscribe
Cyprus1111413► Subscribe
South Africa200803985► Subscribe
Cyprus1111400► Subscribe
Norway953011► Subscribe
Slovakia281927► Subscribe
Austria497777► Subscribe
Eurasian Patent Organization001406► Subscribe
European Patent Office1601395► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi Aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/036United Kingdom► SubscribePRODUCT NAME: INSULIN LISPRO, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: CH 53290 19951123; CH 53553 19951123; UK EU/1/96/007/001 19960430; UK EU/1/96/007/002 19960430; UK EU/1/96/007/003 19960430
00597Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
0596Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
C0052France► SubscribePRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
2013010Lithuania► SubscribePRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
C0035France► SubscribePRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121
C0055France► SubscribePRODUCT NAME: TELITHROMYCINE; REGISTRATION NO/DATE: EU/1/01/191/001 20010709
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
C0085France► SubscribePRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Daiichi Sankyo
AstraZeneca
Cipla
Teva
Fish and Richardson
Express Scripts
Chubb
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot